Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients. by Powe, N, Griffiths, R, Watson, A, Anderson, G, de Lissovoy, G, Greer, J, Herbert, R, Milam, R, Whelton, P

Early dosing practices and effectiveness of recombinant human erythropoietin. by Powe, N, Griffiths, R, Greer, J, Watson, A, Anderson, G, de Lissovoy, G, Herbert, R, Eggers, P, Milam, R, Whelton, P

Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval. by Powe, N, Griffiths, R, de Lissovoy, G, Anderson, G, Watson, A, Greer, J, Herbert, R, Eggers, P, Milam, R, Whelton, P

The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients. by de Lissovoy, G, Powe, N, Griffiths, R, Watson, A, Anderson, G, Greer, J, Herbert, R, Eggers, P, Milam, R, Whelton, P